October 2023 – FloBio Receives FDA’s Breakthrough Device Designation For Bleeding Risk Diagnostic Test. Rapid Detection of Modern Blood Thinners Could Reduce Preventable Complications In US Hospitals – Learn More
June 2023 – Data presented at ISTH (International Society of Thrombosis and Haemostasis). Rapid Measurement of DOAC Concentration and Platelet Function Using Whole Blood in a Disposable Microfluidic Device
May 2022 – Association for Diagnostic and Lab Medicine (formerly AACC, the American Association of Clinical Chemistry) selects FloBio as a Semi-Finalist in the AACC Disruptive Technology Competition.
November 2022 – Jerri Ann Thatcher, named CEO of the Year by Penn Center for Innovation Ventures
July 2022 — Data presented at ISTH. Whole blood microfluidics to assess direct oral anticoagulant (DOAC) activity in neonatal cardiac patients.
May 2022 – FloBio awarded National Institute of Health (NIH) Phase 2 SBIR to advance the development of “A Rapid Microfluidic diagnostic assay for the measurement of Direct Oral Anticoagulants from patient whole blood.
July 2021 – Data presented at ISTH. “Rapid Detection of DOAC in DVT Patients using a Single-use microfluidic Chip under Whole Blood Flow.”
February 2021 – FloBio secures exclusive worldwide license for novel in-vitro-diagnostic technology being developed for bleeding and thrombotic risk.
January 2021 – Ben Franklin Technology Partners of Southeastern PA invest in early-stage startups, including FloBio.
November 2020 – FloBio awarded a National Science Foundation (NSF) SBIR grant to advance development of an “Automated assay to determine coagulant status in emergency care.”
October 2020 – FloBio selected as a 2020 Falling Walls Finalist for “Science Startup Breakthrough of the Year.”
September 2020 – Publication of FloBio technology, establishes proof of concept. Scalable manufacture of a disposable, storage stable eight-channel microfluidic device for rapid testing of platelet, coagulation, and drug function under whole blood flow. Biomicrofluidics.
August 2020 – FloBio granted an NIH SBIR grant to pursue development of a “Point-of-Care device for testing neonate platelet function.”
July 2020 – Data presented at ISTH. “Point of Care and Storage-Stable, Single Use 8-Channel Microfluidic Chip for Rapid Testing of DOACs and DOAC Reversal Agents under Whole Blood Flow.”
September 2019 – FloBio awarded NIH SBIR grant to pursue development of a “Point-of-care direct oral anticoagulant (DOAC) microfluidic diagnostic.”
July 2018 – Jerri Ann Thatcher joins FloBio as the company’s founding CEO
August 2017 – FloBio spun out of the University of Pennsylvania and becomes a member of the Penn Center for Innovation Ventures UpStart Incubator